Once the patient was transferred to our facility, and the work-up concluded that the patient had plasma cell myeloma, with an underlying early BCL/ABL positive CML and an underlying Jak2 V617F positive myeloproliferative disorder, the patient continued a weekly treatment of bortezomib and anti-CML therapy was initiated. The gene discussed is JAK2; the disease is myeloproliferative disorder.